Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivo

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 3, 2011, Pages

  Wei, Hao ^a   Frei, Balz ^a,b   Beckman, Joseph S ^a,b   Zhang, Wei Jian ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Copper; Endothelium; Inflammation; Lipopolysaccharide; Tetrathiomolybdate

Indexed keywords

CERULOPLASMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MOLYBDENUM; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; TETRATHIOMOLYBDATE AMMONIUM; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; CERULOPLASMIN BLOOD LEVEL; CHELATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; FEMALE; GENETIC TRANSCRIPTION; HEART; IN VIVO STUDY; INFLAMMATION; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CERULOPLASMIN; CHELATING AGENTS; CHEMOKINE CCL2; COPPER; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MOLYBDENUM; NF-KAPPA B; OXIDATION-REDUCTION; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80052333340     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01299.2010     Document Type: Article

References (84)

1. Alvarez HM, Xue Y, Robinson CD, Canalizo-Hernandez MA, Marvin RG, Kelly RA, Mondragon A, Penner-Hahn JE, O'Halloran TV. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science 15: 331-334, 2010.
2. Awadallah SM, Hamad M, Jbarah I, Salem NM, Mubarak MS. Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease. Clinica Chimica Acta 365: 330-336, 2006.
3. Babu U, Failla ML. Copper status and function of neutrophils are reversibly depressed in marginally and severely copper-deficient rats. J Nutr 120: 1700-1709, 1990.
4. Bertinato J, L'Abbe MR. Maintaining copper homeostasis: regulation of copper-trafficking proteins in response to copper deficiency or overload. J Nutr Biochem 15: 316-322, 2004.
5. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10: 416-421, 2004.
6. Bo S, Durazzo M, Gambino R, Berutti C, Milanesio N, Caropreso A, Gentile L, Cassader M, Cavallo-Perin P, Pagano G. Associations of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in adults. J Nutr 138: 305-310, 2008.
7. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
8. Bremner I, Mills CF, Young BW. Copper metabolism in rats given dior trithiomolybdates. J Inorg Biochem 16: 109-119, 1982.
9. Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 7: 11-20, 2003.
10. Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98: 2160-2167, 2004.
11. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6: 1-10, 2000.
12. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51: 545-554, 1994.
13. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48: 42-47, 1991.
14. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141: 210-216, 2003.
15. El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 14: 163-175, 1981.
16. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264, 2001.
17. Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, Buchele B, Syrovets T, Simmet T, Rouis M. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-betaboswellic acid in LPS-challenged ApoE-/-mice. Arterioscler Thromb Vasc Biol 28: 272-277, 2008.
18. Cui JZ, Wang XF, Hsu L, Matsubara JA. Inflammation induced by photocoagulation laser is minimized by copper chelators. Lasers Med Sci 24: 653-657, 2009.
19. Dastych M. Copper-biochemistry, metabolism and physiologic function. Cas Lek Cesk 136: 670-673, 1997.
20. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143: 205-211, 1999.
21. Donate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, Mazar AP. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 98: 776-783, 2008.
22. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105: 1158-1161, 2002.
23. Fan H, Sun B, Gu Q, Lafond-Walker A, Cao S, Becker LC. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 282: H1778-H1786, 2002.
24. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 275: 11058-11063, 2000.
25. Ferns GA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the Blue Janus. Atherosclerosis 133: 139-152, 1997.
26. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Rad Biol Med 28: 1735-1744, 2000.
27. Gitlin JM, Loftin CD. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovasc Res 81: 400-407, 2009.
28. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 46: 469-480, 1981.
29. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773-778, 1999.
30. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281, 1998.
31. Hou G, Dick R, Abrams GD, Brewer GJ. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146: 299-303, 2005.
32. Hu GF. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 69: 326-335, 1998.
33. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 28: 1379-1386, 2000.
34. Hynes M, Lamand M, Montel G, Mason J. Some studies on the metabolism and the effects of 99Mo-and 35S-labelled thiomolybdates after intravenous infusion in sheep. Br J Nutr 52: 149-158, 1984.
35. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 165: 3541-3544, 2000.
36. Jones HB, Gooneratne SR, Howell JM. X-ray microanalysis of liver and kidney in copper loaded sheep with and without thiomolybdate administration. Res Vet Sci 37: 273-282, 1984.
37. Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE, Tonks NK, Mazar AP, Donate F. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 105: 7147-7152, 2008.
38. Kennedy T, Ghio AJ, Reed W, Samet J, Zagorski J, Quay J, Carter J, Dailey L, Hoidal JR, Devlin RB. Copper-dependent inflammation and nuclear factor-kappaB activation by particulate air pollution. Am J Respir Cell Mol Biol 19: 366-378, 1998.
39. Kim WJ, Chereshnev I, Gazdoiu M, Fallon JT, Rollins BJ, Taubman MB. MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem Biophys Res Commun 310: 936-942, 2003.
40. Kisker C, Schindelin H, Baas D, Retey J, Meckenstock RU, Kroneck PM. A structural comparison of molybdenum cofactor-containing enzymes. FEMS Microbiol Rev 22: 503-521, 1998.
41. Kisker C, Schindelin H, Rees DC. Molybdenum-cofactor-containing enzymes: structure and mechanism. Annu Rev Biochem 66: 233-267, 1997.
42. Lewis AJ. The role of copper in inflammatory disorders. Agents Actions 15: 513-519, 1984.
43. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 91: 4B-8B, 2003.
44. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
45. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 63: 797S-811S, 1996.
46. Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24: 23-35, 1979.
47. Lowndes SA, Sheldon HV, Cai S, Taylor JM, Harris AL. Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvas Res 77: 314-326, 2009.
48. Mandinov L, Mandinova A, Kyurkchiev S, Kyurkchiev D, Kehayov I, Kolev V, Soldi R, Bagala C, de MuinckED, Lindner V, Post MJ, Simons M, Bellum S, Prudovsky I, Maciag T. Copper chelation represses the vascular response to injury. Proc Natl Acad Sci USA 100: 6700-6705, 2003.
49. Mandinov L, Moodie KL, Mandinova A, Zhuang Z, Redican F, Baklanov D, Lindner V, Maciag T, Simons M, de Muinck ED. Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries. Am J Physiol Heart Circ Physiol 291: H2692-H2697, 2006.
50. Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O. Cu/Zn superoxide dismutase plays important role in immune response. J Immunol 170: 2993-3001, 2003.
51. Mason J, Lamand M, Hynes MJ. 99Mo metabolism in sheep after the intravenous injection of [99Mo] thiomolybdates. J Inorg Biochem 19: 153-164, 1983.
52. McAuslan BR, Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res 130: 147-157, 1980.
53. McElwee MK, Song MO, Freedman JH. Copper activation of NFkappaB signaling in HepG2 cells. J Mol Biol 393: 1013-1021, 2009.
54. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101: 10679-10684, 2004.
55. Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 14: 189-207, 1981.
56. Muegge K, Williams TM, Kant J, Karin M, Chiu R, Schmidt A, Siebenlist U, Young HA, Durum SK. Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science 246: 249-251, 1989.
57. Mukhopadhyay CK, Fox PL. Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant. Biochemistry 37: 14222-14229, 1998.
58. Omoto A, Kawahito Y, Prudovsky I, Tubouchi Y, Kimura M, Ishino H, Wada M, Yoshida M, Kohno M, Yoshimura R, Yoshikawa T, Sano H. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 7: R1174-R1182, 2005.
59. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 519: 23-29, 2002.
60. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2: 617-622, 2003.
61. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 1: 701-706, 2003.
62. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62: 4854-4859, 2002.
63. Park SK, Yang WS, Han NJ, Lee SK, Ahn H, Lee IK, Park JY, Lee KU, Lee JD. Dexamethasone regulates AP-1 to repress TNF-alpha induced MCP-1 production in human glomerular endothelial cells. Nephrol Dial Transplant 19: 312-319, 2004.
64. Percival SS. Copper and immunity. Am J Clin Nutr 67: 1064S-1068S, 1998.
65. Prince LS, Okoh VO, Moninger TO, Matalon S. Lipopolysaccharide increases alveolar type II cell number in fetal mouse lungs through Toll-like receptor 4 and NF-kappaB. Am J Physiol Lung Cell Mol Physiol 287: L999-L1006, 2004.
66. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-1672, 2003.
67. Reelfs O, Tyrrell RM, Pourzand C. Ultraviolet a radiation-induced immediate iron release is a key modulator of the activation of NF-kappaB in human skin fibroblasts. J Invest Dermatol 122: 1440-1447, 2004.
68. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
69. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20: 1556-1563, 1974.
70. Seeger H, Mueck AO, Lippert TH. The inhibitory effect of endogenous estrogen metabolites on copper-mediated in vitro oxidation of LDL. Int J Clin Pharmacol Ther 36: 383-385, 1998.
71. Suska F, Gretzer C, Esposito M, Emanuelsson L, Wennerberg A, Tengvall P, Thomsen P. In vivo cytokine secretion and NF-kappaB activation around titanium and copper implants. Biomaterials 26: 519-527, 2005.
72. Tanaka C, Kamata H, Takeshita H, Yagisawa H, Hirata H. Redox regulation of lipopolysaccharide (LPS)-induced interleukin-8 (IL-8) gene expression mediated by NF kappa B and AP-1 in human astrocytoma U373 cells. Biochem Biophys Res Commun 232: 568-573, 1997.
73. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 74: 13-33, 1996.
74. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106: 1985-1990, 2002.
75. Volker W, Dorszewski A, Unruh V, Robenek H, Breithardt G, Buddecke E. Copper-induced inflammatory reactions of rat carotid arteries mimic restenosis/arteriosclerosis-like neointima formation. Atherosclerosis 130: 29-36, 1997.
76. Vruwink KG, Gershwin ME, Sachet P, Halpern G, Davis PA. Modification of human LDL by in vitro incubation with cigarette smoke or copper ions: implications for allergies, asthma and atherosclerosis. J Investig Allergol Clin Immunol 6: 294-300, 1996.
77. Wang X, Zhang J, Su Y, Li C, Feng W, Zhang Z. Effect of thermal injury on LPS-mediated Toll signaling pathways by murine peritoneal macrophages: inhibition of DNA-binding of transcription factor AP-1 and NF-kappaB and gene expression of c-fos and IL-12p40. Sci China C Life Sci 45: 613-622, 2002.
78. Westerterp M, Berbee JF, Pires NM, van Mierlo GJ, Kleemann R, Romijn JA, Havekes LM, Rensen PC. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 116: 2173-2181, 2007.
79. Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 228: 105-113, 2008.
80. Xiong S, She H, Sung CK, Tsukamoto H. Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease. Alcohol 30: 107-113, 2003.
81. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H. Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem 278: 17646-17654, 2003.
82. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104: 3103-3108, 2001.
83. Yang QW, Mou L, Lv FL, Wang JZ, Wang L, Zhou HJ, Gao D. Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL. Biorheology 42: 225-236, 2005.
84. Zhang WJ, Frei B. Intracellular metal ion chelators inhibit TNFalphainduced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. Free Radic Biol Med 34: 674-682, 2003.